Dr. Nigel McCracken

Prior to joining Virax, Dr. McCracken was the Chief Scientific Officer at BerGenBio AsA (OTC: BRRGF, LSE: 0RU5 and GR: 7BG) where he drove the plan for BerGenBio AsA’s companion diagnostics and assay development. Prior to that role, he served as COO at NuCana PLC (Nasdaq: NCNA and GR: N04A), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, where he provided oversight and direction to the operations of the business, research and development and execution of corporate strategy. Dr McCracken brings over 25 years of research & development experience in drug development within a number of indications including oncology and infectious disease. Dr. McCracken obtained a Master’s degree in Clinical Pharmacology from Kings College London, a Doctor of Philosophy degree in Biochemical Toxicology from the University of Newcastle Upon Tyne, and a Bachelor of Science degree in Biochemistry and Pharmacology from Strathclyde University.